PT - JOURNAL ARTICLE AU - Meagan P. O’Brien AU - Eduardo Forleo-Neto AU - Neena Sarkar AU - Flonza Isa AU - Peijie Hou AU - Kuo-Chen Chan AU - Bret J. Musser AU - Katharine J. Bar AU - Ruanne V. Barnabas AU - Dan H. Barouch AU - Myron S. Cohen AU - Christopher B. Hurt AU - Dale R. Burwen AU - Mary A. Marovich AU - Ingeborg Heirman AU - John D. Davis AU - Kenneth C. Turner AU - Divya Ramesh AU - Adnan Mahmood AU - Andrea T. Hooper AU - Jennifer D. Hamilton AU - Yunji Kim AU - Lisa A. Purcell AU - Alina Baum AU - Christos A. Kyratsous AU - James Krainson AU - Richard Perez-Perez AU - Rizwana Mohseni AU - Bari Kowal AU - A. Thomas DiCioccio AU - Neil Stahl AU - Leah Lipsich AU - Ned Braunstein AU - Gary Herman AU - George D. Yancopoulos AU - David M. Weinreich AU - for the Covid-19 Phase 3 Prevention Trial Team TI - Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection AID - 10.1101/2021.06.14.21258569 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.14.21258569 4099 - http://medrxiv.org/content/early/2021/06/14/2021.06.14.21258569.short 4100 - http://medrxiv.org/content/early/2021/06/14/2021.06.14.21258569.full AB - Background Casirivimab and imdevimab administered together (REGEN-COV™) markedly reduces the risk of hospitalization or death in high-risk, symptomatic individuals with COVID-19. Here, we report phase 3 results of early treatment of asymptomatic, SARS-CoV-2–positive adults and adolescents with subcutaneous REGEN-COV.Methods Individuals ≥12 years of age were eligible if identified within 96 hours of a household contact being diagnosed as SARS-CoV-2-positive; 314 were randomized 1:1 to receive subcutaneous REGEN-COV 1200mg or placebo. The primary endpoint was the proportion of infected participants without evidence of prior immunity (i.e., SARS-CoV-2-RT-qPCR–positive/seronegative) who subsequently developed symptomatic Covid-19 during a 28-day efficacy assessment period.Results Subcutaneous REGEN-COV 1200mg significantly prevented progression from asymptomatic to symptomatic disease compared with placebo (31.5% relative risk reduction; 29/100 [29.0%] vs. 44/104 [42.3%], respectively; P=0.0380). REGEN-COV also reduced the overall population burden of high viral load weeks (39.7% reduction vs. placebo; 48 vs. 82 total weeks; P=0.0010) and of symptomatic weeks (45.3% reduction vs. placebo; 89.6 vs. 170.3 total weeks; P=0.0273), the latter corresponding to an approximately 5.6-day reduction per symptomatic participant. Six placebo-treated participants had a Covid-19-related hospitalization or ER visit versus none for those receiving REGEN-COV. The proportion of participants receiving placebo who had ≥1 treatment-emergent adverse events was 48.1% compared to 33.5% for those receiving REGEN-COV, including Covid-19-related (39.7% vs. 25.8%, respectively) or non-Covid-19-related (16.0% vs. 11.0%, respectively) events.Conclusions Subcutaneous REGEN-COV 1200mg prevented progression from asymptomatic to symptomatic infection, reduced the duration of high viral load and symptoms, and was well tolerated.(ClinicalTrials.gov number, NCT04452318.)Competing Interest StatementICMJE disclosure forms provided by the authors are available with the full text of this article.Clinical TrialNCT04452318Funding StatementSupported by Regeneron Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd. This trial was conducted jointly with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The CoVPN is supported by cooperative agreement awards from NIAID NIH. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The work on this study was supported by CoVPN award number UM1AI068619.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the following ethics review boards: WCG IRB, Puyallup, WA (IRB00000533); Lifespan Rhode Island Hospital IRB 2, Providence, RI (IRB# 00004624); Stanford University Research Compliance Office, Palo Alto, CA (IRB# 00004593); Geisinger Institutional Review Board GRIB, Danville, PA (IRB00008345); Advarra IRB, Columbia, MD (IRB00000971).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.